The evolution of mendelian randomization for investigating drug effects.
View / Open Files
Publication Date
2022-02-03Journal Title
PLoS medicine
ISSN
1549-1277
Volume
19
Issue
2
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Gill, D., & Burgess, S. (2022). The evolution of mendelian randomization for investigating drug effects.. PLoS medicine, 19 (2) https://doi.org/10.1371/journal.pmed.1003898
Abstract
Dipender Gill and Stephen Burgess discuss the accompanying study by James Yarmolinsky and colleagues investigating the associations between genetically-proxied inhibition of antihypertensive drug targets and risk of common cancer subtypes using Mendelian randomization.
Keywords
Humans, Colorectal Neoplasms, Antihypertensive Agents, Angiotensin-Converting Enzyme Inhibitors, Risk Factors, Blood Pressure, Genetic Variation, Genome-Wide Association Study, Mendelian Randomization Analysis
Identifiers
PMC8812877, 35113864
External DOI: https://doi.org/10.1371/journal.pmed.1003898
This record's URL: https://www.repository.cam.ac.uk/handle/1810/334718
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.